In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

The antiplatelet therapy and pro-inflammatory cytokines with stable coronary artery disease: is there any connection?

Session Poster Session 1

Speaker Andrey Vorobev

Congress : Heart Failure 2019

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease - Pathophysiology and Mechanisms
  • Session type : Poster Session
  • FP Number : P498

Authors : A Vorobev (Ulyanovsk,RU), VI Ruzov (Ulyanovsk,RU), LG Komarova (Ulyanovsk,RU), AS Komarov (Ulyanovsk,RU)

A Vorobev1 , VI Ruzov1 , LG Komarova1 , AS Komarov1 , 1Ulyanovsk State University - Ulyanovsk - Russian Federation ,


The connection between cytokine inflammation and atherothrombosis suggests evaluability of

the antiplatelet effect by values of pro-inflammatory interleukins, notably IL-1ß and IL-6.

Purpose. The goal is to study the connection between the antiplatelet effect and cytokine

inflammation with stable CAD.

Methods. The evaluation of thrombocyte aggregation against mono- and dual antiplatelet therapy

was carried out in 147 patients with stable clinical progression of CAD, of whom 121 patients

received aspirin mono-therapy, while 26 patients received clopidogrel/aspirin therapy. The

platelet aggregation was assessed by a spontaneous and adenosine diphosphate (ADP) - induced

aggregometry. IL-1ß and IL-6 concentration was determined by a solid-phase enzyme


Results. The stable progression of CAD is characterized by the absence of activation of cytokine

inflammation (in IL-1ß and IL-6 levels) in 73% of patients. Subclinical inflammation was seen in

23% of patients during both mono- and dual antiplatelet therapy, which was reflected by higher-

than-normal values of predominantly IL-6 (12% vs. 1%).

Evaluation of the connection between the cytokine activity and the spontaneous and ADP-

induced platelet aggregation in patients undergoing coronary revascularization showed

insufficient anti-inflammatory effect of aspirin mono-therapy vs. the combined effect of aspirin

and clopidogrel, which was expressed by higher levels of pro-inflammatory interleukins IL-1ß

and IL-6 (?2=4.01, p=0.04). At the same time, spontaneous platelet aggregation activity was

observed during mono or double antiplatelet therapy, mainly in stented patients (23%) vs.

shunting patients (7%), and correlated with higher-than-normal values of pro-inflammatory


Conclusion. The efficacy of antiplatelet therapy correlates with low ADP-induced platelet

activity and cytokine inflammation. Persistence of high spontaneous platelet aggregation during

antiplatelet therapy, mainly in stented patients, against the higher-than-normal values of pro-

inflammatory interleukins indicates subclinical inflammation and thrombogenic risk retention.

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are